Intracranial Mycotic Aneurysm in a Left Ventricular Assist Device Patient: A Complication to Avoid

Pavida Pachariyanon¹, Arunee T. Motes¹, Nandini Nair²

1. Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, USA 2. Cardiology, Texas Tech University Health Sciences Center, Lubbock, USA

Corresponding author: Nandini Nair, nandini.nair@gmail.com

Abstract

In the current era of the increasing use of left ventricular assist devices (LVADs) as a bridge to transplant or destination therapy, early diagnosis and therapy of complications are imperative to provide a better quality of life and improve outcomes. This case illustrates how superficial infections can lead to drastic complications in the setting of LVADs. The lack of signs and symptoms of systemic inflammatory response could be explained by cellular immunity impairment in patients on LVAD support. The formation of aneurysms is enhanced in the LVAD population due to altered hemodynamic physiology. It is possible that the combination of impaired cellular immunity and altered hemodynamics of the present-day continuous flow LVADs increases the risk of mycotic aneurysm formation and rupture in patients infected with less virulent organisms.

Categories: Cardiac/Thoracic/Vascular Surgery, Cardiology, Infectious Disease

Keywords: lvad, mycotic aneurysm, cellular immunity, intracranial infectious aneurysm

Introduction

Left ventricular assist devices (LVADs) have been increasingly used as a bridge to transplant and for destination therapy in end-stage heart failure patients. The event rate of LVAD-related infection in the first year after implantation remains high, approximately 30% to 40% [1]. LVAD-related infections are also seen with the increasing use of third-generation LVADs [2]. We present here a rare case of a ruptured intracranial mycotic aneurysm secondary to *Staphylococcus epidermidis* (*S. epidermidis*) bacteremia in the setting of a superficial driveline infection.

Case Presentation

A 53-year-old African American male with non-ischemic cardiomyopathy underwent Heartmate II LVAD (Abbott Laboratories, Chicago, Illinois) implantation as destination therapy. He presented with intermittent yellowish discharge around the driveline exit site approximately 140 days post-implantation. The patient was afebrile. The physical examination showed mild redness, sloughed skin, and gelatinous discharge around the driveline exit site. The physical examination was otherwise unremarkable. Laboratory studies showed a normal white cell count of 6500/mm³. Multiple blood cultures grew oxacillin-resistant *S. epidermidis* from 140 days onwards for the next 60 days. He was treated with local wound care and sequentially with clindamycin, amoxicillin-clavulanic acid, and doxycycline orally depending on the susceptibilities. However, the patient continued to have multiple episodes of breakthrough oxacillin-resistant *S. epidermidis* bacteremia despite the resolution of the wound around the driveline exit site. Intravenous vancomycin was initiated. Computed tomography (CT) of the abdomen and chest showed no fluid collection around the LVAD or driveline. The trans-esophageal echocardiogram was unremarkable. Intravenous vancomycin was switched to daptomycin due to difficulty in assessing accurate levels.

Approximately two weeks after the intravenous antibiotic was initiated, the patient experienced sudden onset severe headache, profuse sweating, acute right hemiparesis, and rapidly became unresponsive. Non-contrast CT of the head showed large intraparenchymal hemorrhage in the left external capsule, a perisular region with subarachnoid hemorrhage, causing subfalcine herniation 10 mm toward the right (Figure 1). CT angiography of the head and neck showed a 10.7 x 9.6 x 7.6 mm bilobed-shaped fusiform aneurysm arising from the distal aspect of the posterior trunk of the left middle cerebral artery (Figure 2). His international normalized ratio was 1.25 while partial thromboplastin activation time was 34 seconds at the time. The patient underwent emergent left craniectomy with hematoma evacuation and aneurysm clipping. The patient's neurologic status continued to deteriorate until his demise.

Review began 09/09/2020

Review ended 12/25/2020

Published 12/31/2020

© Copyright 2020

Pachariyanon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Pachariyanon P, Motes A T, Nair N (December 31, 2020) Intracranial Mycotic Aneurysm in a Left Ventricular Assist Device Patient: A Complication to Avoid. Cureus 12(12): e12401. DOI 10.7759/cureus.12401

FIGURE 1: Non-contrast CT of the head showed a large intraparenchymal hemorrhage in the left external capsule, peri-insular region with subarachnoid hemorrhage

CT: computed tomography

FIGURE 2: CT angiography of the head and neck showed a 10.7 x 9.6 x 7.6 mm bilobed-shaped fusiform aneurysm arising from the distal aspect of the posterior trunk of the left middle cerebral artery

CT: computed tomography

Discussion

Approximately 40% of patients develop an infection after an LVAD implant with a higher incidence occurring early after implantation [1]. The LVAD-related infection has been associated with stroke, predominantly hemorrhagic stroke, and decreased one-year survival in this population [1-2]. Intracranial hemorrhage secondary to systemic infection could be a consequence of hemorrhagic transformation of an ischemic stroke, primary hemorrhage, and subarachnoid hemorrhage from septic emboli, vascular friability, or ruptured mycotic aneurysm as in infective endocarditis patients. Non-physiologic continuous-flow LVADs and the need for anticoagulation increase the risk of intracranial hemorrhage in the LVAD population [3].

Infectious intracranial aneurysm (IIA) refers to an aneurysm arising secondary to the inflammatory reaction

caused by the microbial infection, predominantly bacterial. IIA is rare, only comprising 0.7%-5.4% of all intracranial aneurysms and usually associated with infective endocarditis [4]. It is interesting that *S. epidermidis* being less virulent still causes mycotic aneurysm formation in LVAD patients [5-11]. In this case, the patient did not present with signs or symptoms of systemic inflammatory response syndrome (SIRS). In another study, less than half of LVAD patients with bloodstream infection (BSI) met SIRS criteria [12]. The lack of signs and symptoms of SIRS, in this case, may be explained by cellular immunity impairment in the LVAD population [13-14]. It has been noted that *Staphylococcus* species and fungus are most commonly seen after LVAD implantation, suggesting that cellular immunity is impaired among LVAD recipients [15].

Driveline infections can be difficult to distinguish from driveline site trauma, which may lead to inadequate treatment, causing endovascular seeding of microorganisms from biofilm formation, thereby forming a focus for persistent bacteremia. Treatment of LVAD-related bacteremia typically includes four to six weeks of parenteral antibiotics, followed by long-term suppressive therapy with oral antibiotics and surgical debridement. Currently, there are no established guidelines for the surveillance of IIAs in active BSI without neurological manifestations in the LVAD population. This case illustrates that IIA surveillance and early diagnosis in asymptomatic LVAD patients could prevent fatality in this population. An abnormal state of monocyte and T-cell activation results in increased susceptibility of circulating CD4 T cells to activated cell death. Such abnormal immune activation leads to defects in cellular immunity resulting in a serious infection. The increased T-cell activation and selective loss of Th1 cytokine-producing CD4 T cells drive LVAD patients to develop B-cell hyperactivity and poorly regulated immunoglobulin syntheses due to unopposed production of Th2 cytokines and increased Ligand-CD40 interactions [14]. It is postulated that immune dysregulation and function is a result of foreign biomaterial associated T-cell activation. This can only be prevented if the biomaterials are manufactured with altered physical properties or pharmacological inhibition of T cell response.

Conclusions

Ruptured IIA is associated with high mortality. Early recognition and aggressive intervention of asymptomatic IIA in LVAD patients with active BSI may prevent the morbidity and mortality associated with aneurysm rupture. Further guidelines to actively monitor intracranial aneurysms in continuous-flow LVAD patients are warranted. Further investigation of immune dysregulation in LVAD recipients would pave the path to a better understanding of susceptibility to infections in this population.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Jezovnik MK, Gregoric ID, Poredos P: Medical complications in patients with LVAD devices. *e-Journal of Cardiology Practice*. 2017, 14:37.
2. Trachtenburg BH, Corero-Reyes A, Elias B, Loebe M: A review of infections in patients with left ventricular assist devices: prevention, diagnosis, and management. *Methodist DeBakey Cardiovasc J*. 2015, 11:28-32. [10.14797/mdcj-11-1-28](https://doi.org/10.14797/mdcj-11-1-28)
3. Jillella DV, Wisco DR: Infectious causes of stroke. *Curr Opin Infect Dis*. 2019, 32:285-292. [10.1097/QCO.0000000000000547](https://doi.org/10.1097/QCO.0000000000000547)
4. Ducruet AF, Hickman ZL, Zacharia BE, Narula R, Grobelny BT, Gorski J, Connolly ES: Intracranial infectious aneurysms: a comprehensive review. *Neurosurgical Rev*. 2010, 33:37-46. [10.1007/s10143-009-0233-1](https://doi.org/10.1007/s10143-009-0233-1)
5. Hill JA, Mokadam NA, Rakita RM: Intracranial mycotic aneurysm associated with left ventricular assist device infection. *Ann Thorac Surg*. 2014, 98:1088-1089. [10.1016/j.athoracsur.2013.10.094](https://doi.org/10.1016/j.athoracsur.2013.10.094)
6. Lee T, Buletko AB, Matthew J, Cho SM: Bloodstream infection is associated with subarachnoid hemorrhage and infectious intracranial aneurysm in the left ventricular assist device. *Perfusion*. 2020, 35:117-120. [10.1177/0267659119858853](https://doi.org/10.1177/0267659119858853)
7. Voruganti D, Gajurel K, Bhama JK, Cotarlan V: Ruptured intracranial mycotic aneurysm in infective endocarditis with left ventricular assist device and implantable cardiac defibrillator device: a clinical course. *Transplant Proc*. 2018, 50:4064-4066. [10.1016/j.transproceed.2018.08.027](https://doi.org/10.1016/j.transproceed.2018.08.027)
8. Bentz B, Hupcey JE, Polomano RC, Boehmer JP: A retrospective study of left ventricular assist device-related infections. *J Cardiovasc Manag*. 2004, 15:9-16.
9. Chinn R, Dembitsky W, Eaton L, Chillcott S, Stahovich M, Rasmussen B, Pagami F: Multicenter experience: prevention and management of left ventricular assist device infections. *ASAIO J*. 2005, 51:461-470. [10.1097/01.mat.0000170620.65279.aa](https://doi.org/10.1097/01.mat.0000170620.65279.aa)
10. Kasirajan V, McCarthy PM, Hoercher KJ, Starling RC, Young JB, Banbury MK, Smedira NG: Clinical experience with long-term use of implantable left ventricular assist devices: indications, implantation, and outcomes. *Semin Thorac Cardiovasc Surg*. 2000, 12:229-237. [10.1053/stcs.2000.9667](https://doi.org/10.1053/stcs.2000.9667)

11. Martin J, Friesewinkel O, Benk C, Sorg S, Schultz S, Beyersdorf F: Improved durability of the HeartMate XVE left ventricular assist device provides safe mechanical support up to 1 year but is associated with high risk of device failure in the second year. *J Heart Lung Transplant*. 2006, 25:384-390. [10.1016/j.healun.2005.11.437](https://doi.org/10.1016/j.healun.2005.11.437)
12. Kyvernitis A, Pappas O, Farmakiotis D, Horn ET, Benza RB, Bailey SH, Agarwal R: Bloodstream infections in continuous flow left ventricular assist device recipients: diagnostic and clinical implications. *ASAIO J*. 2019, 65:798-805. [10.1097/MAT.0000000000000881](https://doi.org/10.1097/MAT.0000000000000881)
13. Kimball PM, Flattery M, McDougan F, Kasirajan V: Cellular immunity impaired among patients on left ventricular assist device for 6 months. *Ann Thorac Surg*. 2008, 85:1656-1661. [10.1016/j.athoracsur.2008.01.050](https://doi.org/10.1016/j.athoracsur.2008.01.050)
14. Radley G, Laura Pieper I, Thomas BR, Hawkins K, Thornton CA: Artificial shear stress effects on leukocytes at a biomaterial interface. *Artif Organs*. 2019, 43:139-151. [10.1111/aor.13409](https://doi.org/10.1111/aor.13409)
15. Itescu S, Andersmit JH, Kocher AA, Schuster MD: Immunobiology of left ventricular assist devices. *Prog Cardiovasc Dis*. 2000, 43:67-80. [10.1053/pcad.2000.7191](https://doi.org/10.1053/pcad.2000.7191)